Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Conexeu Sciences announced progress in manufacturing scale-up and standardized formulation methods for its lead CXU™ wound care device candidate with its CDMO. The company is advancing activities to support a planned 510(k) premarket notification submission to the FDA during the first quarter of 2027.
Key figures
- Drug Name
- Ten Minute Tissue™
- Gelation time
- approximately ten minutes
- Submission target
- Q1 2027
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.